Journal of Neurology

, Volume 246, Issue 12, pp 1127–1133 | Cite as

Risk factors for levodopa-induced dyskinesias in Parkinson’s disease

  • F. Grandas
  • Maria Luisa Galiano
  • Cesar Tabernero
Original communication

Abstract

To identify putative risk factors for levodopa-induced dyskinesias we studied the effect of several clinical variables on the occurrence of dyskinesias in a series of 168 consecutive patients with Parkinson’s disease treated for at least 6 months with levodopa. Of these, 108 (64%) developed dyskinesias after a mean duration of levodopa treatment of 51.4 ± 43.3 months. Patients tended to suffer dyskinesias on the side of the body first affected by Parkinson’s disease. The overall probability of developing dyskinesias increased with levodopa treatment duration, about 10% per year during the first 7 years. Univariate and multivariate logistic regression analysis identified the age at onset of Parkinson’s disease (OR 0.923; 95% CI 0.883–0.964) and the initial levodopa dose (mean dose of the first 6 months of treatment; OR 1.004; 95% CI 1.002–1.006) as the main independent predictors. Survival curves showed that onset of Parkinson’s disease at age 50 years or before (logrank, P < 0.05) and initial levodopa treatment with more than 600 mg/day (logrank, P < 0.05) were associated with a higher risk for the appearance of dyskinesias.

Key words Dyskinesias Levodopa Risk factors Parkinson’s disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Steinkopff Verlag 1999

Authors and Affiliations

  • F. Grandas
    • 1
  • Maria Luisa Galiano
    • 2
  • Cesar Tabernero
    • 1
  1. 1.Servicio de Neurología, Hospital General Universitario Gregorio Marañón, Doctor Esquerdo 46, E-28007 Madrid, Spain Tel.: +91-5868339, Fax: +91-5868018ES
  2. 2.Ambulatorio de Especialidades de la Seguridad Social de Moratalaz, Madrid, SpainES

Personalised recommendations